NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis announced today that it has signed an agreement with Germany's Merck to develop and commercialize a new liquid biopsy-based RAS biomarker test for metastatic colorectal cancer based on its Idylla PCR-based diagnostics platform.

According to Biocartis, the new test will comprise two Idylla cartridges and be designed to detect an extended panel of RAS mutations while also providing a BRAF V600 mutation analysis, allowing clinicians to evaluate the mutation status of both biomarker types simultaneously.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.